Targeted Gold Nanoparticles (AuNPs) for Potent Alpha-Particle Radiotherapy of Brain Cancer
Abstract
Glioblastoma (GBM) is the most common and aggressive brain cancer. Even with the highest first year cost (> $120,000), the prognosis for GBM patients is dismal. Therefore, it is of great clinical significance to develop novel therapeutic approaches to improve GBM treatment efficacy. Alpha particle radiation therapy with high linear energy transfer (80 keV/mu m) has a potent therapeutic effect independent of dose rate, cell cycle, and oxygen concentration. A single alpha-particle track can result in lethal DNA double-strand breaks. Astatine-211 (211At) is an attractive alpha emitter for alpha particle radiation therapy because it has the advantages of an optimal half-life (7.2 h) and no long-lived decay daughter radionuclides thus avoiding toxicity from daughter radionuclide redistribution. However, traditional 211At radiolabeling methods have the challenges of a complicated radiolabeling process and low conjugation efficiency. In this study, we develop targeted gold nanoparticles as a novel 211At delivery nanoplatform for alpha particle radiation therapy. We have demonstrated that the developed gold nanoparticles can selectively accumulate in the brain tumor. We also performed preliminary in vivo toxicity study and therapeutic efficacy test. Experiment results demonstrated that 211At-loaded gold nanoparticles can substantially reduce tumor growth after intratumoral administration using a murine animal model.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2022
- Accession Number
- AD1180657
Entities
People
- Yang Liu
Organizations
- Duke University